[Phe1Ψ(CH2-NH)Gly2]Nociceptin(1-13)NH2 - CAS 213130-17-7
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C61H102N22O14
Molecular Weight:
1367.6
COA:
Inquire
Targets:
Opioid Receptor
Description:
[Phe1Ψ(CH2-NH)Gly2]Nociceptin(1-13)NH2 is the first selective antagonist to prevent the binding of the endogenous ligand orphanin FQ​/Nociceptin (OFQ​/N) at the orphan opioid-​like receptor, demonstrated both in vitro and in vivo. It is selective, competitive antagonism at the nociceptin receptor has also been reported (pA2 = 7.02 and 6.75 in the guinea pig ileum and mouse vas deferens respectively).
Sequence:
FGGFTGARKSARK
(Modifications: Phe-1-Gly-2 peptide bond replace with Psi-(CH2-NH), Lys-13 = C-terminal amide)
Synonyms:
(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanamide; N-[(2S)-2-Amino-3-phenylpropyl]glycylglycyl-L-phenylalanyl-L-threonylglycyl-L-alanyl-L-arginyl-L-lysyl-L-seryl-L-alanyl-L-arginyl-L-lysinamide; N-[(2S)-2-Amino-3-phenylpropyl]-13-L-lysinamide-2-13-orphanin FQ (swine)
Solubility:
Soluble to 0.70 mg/ml in water
Storage:
Store in a cool and dry place (or refer to the Certificate of Analysis).
MSDS:
Inquire
InChIKey:
ZHKMSRDIVOXQKP-YILJZHMHSA-N
InChI:
InChI=1S/C61H102N22O14/c1-35(75-48(87)33-74-59(97)50(37(3)85)83-57(95)45(29-39-18-8-5-9-19-39)77-49(88)32-73-47(86)31-70-30-40(64)28-38-16-6-4-7-17-38)52(90)79-44(23-15-27-72-61(68)69)55(93)81-42(21-11-13-25-63)56(94)82-46(34-84)58(96)76-36(2)53(91)80-43(22-14-26-71-60(66)67)54(92)78-41(51(65)89)20-10-12-24-62/h4-9,16-19,35-37,40-46,50,70,84-85H,10-15,20-34,62-64H2,1-3H3,(H2,65,89)(H,73,86)(H,74,97)(H,75,87)(H,76,96)(H,77,88)(H,78,92)(H,79,90)(H,80,91)(H,81,93)(H,82,94)(H,83,95)(H4,66,67,71)(H4,68,69,72)/t35-,36-,37+,40-,41-,42-,43-,44-,45-,46-,50-/m0/s1
Canonical SMILES:
CC(C(C(=O)NCC(=O)NC(C)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCCN)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCCN)C(=O)N)NC(=O)C(CC1=CC=CC=C1)NC(=O)CNC(=O)CNCC(CC2=CC=CC=C2)N)O
1.Spontaneous transient outward currents: modulation by nociceptin in murine dentate gyrus granule cells.
Shirasaki T;Houtani T;Sugimoto T;Matsuda H Brain Res. 2001 Nov 2;917(2):191-205.
Spontaneous transient outward currents have been found in peripheral neurons and smooth muscle cells, but rarely in central neurons. Using a nystatin-perforated patch clamp technique, we succeeded in recording spontaneous transient outward currents in mouse dentate gyrus granule cells. Nociceptin/orphanin FQ increased the amplitude and frequency of transient outward currents. We consider modulation of spontaneous transient outward currents to be a new means to regulate cell activity in central neurons, and studied their characteristics and mechanism of augmentation. The whole-cell current-voltage relationship showed outward rectification and the reversal potential was close to the equilibrium potential for K+. The frequency of spontaneous transient outward currents increased at depolarized potentials. Tetraethylammonium, iberiotoxin and a Ca2+ chelator BAPTA-AM inhibited spontaneous transient outward currents. These results suggest the involvement of large-conductance Ca2+-activated K+ channels. Single-channel recordings in the inside-out configuration revealed Ca2+-activated K+ channels with a conductance ranging from 82 to 352 pS. The augmenting effect of nociceptin/orphanin FQ was cancelled by [Phe1psi(CH2-NH)Gly2]Nociceptin(1-13)NH2.
2.Modulation of the cardiac autonomic transmission of pithed rats by presynaptic opioid OP4 and cannabinoid CB1 receptors.
Malinowska B;Piszcz J;Koneczny B;Hryniewicz A;Schlicker E Naunyn Schmiedebergs Arch Pharmacol. 2001 Sep;364(3):233-41.
We studied the effects of nociceptin, the endogenous ligand of the opioid OP4 receptor, and of two cannabinoid receptor agonists WIN 55,212-2 and CP-55,940 (0.001-1 micromol/kg each) on the neurogenic tachycardia and bradycardia in pithed rats. Electrical stimulation (1 Hz, 1 ms, 50 V for 10 s) of the preganglionic sympathetic nerve fibres and injection of nicotine 2 micromol/kg or isoprenaline 0.5 nmol/kg increased heart rate by about 70 beats/min (bpm) in pithed rats pretreated with atropine 1.5-2 micromol/kg. The electrically induced tachycardia was reduced dose dependently by nociceptin, WIN 55,212-2 and CP-55,940 (by 60, 30 and 20% at the highest dose, respectively). The OP4 and cannabinoid receptor agonists diminished the nicotine- but not the isoprenaline-stimulated increase in heart rate. In pithed rats pretreated with propranolol 3 micromol/kg, vagal stimulation (5 Hz, 1 ms, 15 V for 10 s) or injection of methacholine (5-10 nmol/kg) decreased heart rate by about 30 bpm. Nociceptin, but not WIN 55,212-2 or CP-55,940 decreased the vagal bradycardia dose dependently (the inhibitory effect of 1 micromol/kg was about 40%). Nociceptin failed to modify the methacholine-induced decrease in heart rate.
3.[Phe1psi(CH2-NH)Gly2]nociceptin-(1-13)-NH2 acts as an agonist of the orphanin FQ/nociceptin receptor in vivo.
Grisel JE;Farrier DE;Wilson SG;Mogil JS Eur J Pharmacol. 1998 Sep 11;357(1):R1-3.
The orphanin FQ/nociceptin (OFQ/N) derivative peptide, [Phe1psi(CH2-NH)Gly2] nociceptin-(1-13)-NH2 (Phe(psi)), has been claimed to be both an antagonist and an agonist of the orphan opioid receptor (ORL1) in different in vitro assays. We now report the dose-dependent inhibition of morphine analgesia by Phe(psi) in mice, an effect parallel to that of OFQ/N. Further, the anti-opioid actions of OFQ/N are not blocked by Phe(psi). Thus, Phe(psi) acts as an ORL1 receptor agonist, not an antagonist, in vivo.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Opioid Receptor Products


CAS 361444-66-8 JDTic

JDTic
(CAS: 361444-66-8)

A 4-phenylpiperidine derivative, for the κ-opioid receptor.

CAS 78123-71-4 DAMGO

DAMGO
(CAS: 78123-71-4)

DAMGO is a highly selective peptide agonist of the μ opioid receptor.

CAS 188119-47-3 NocII

NocII
(CAS: 188119-47-3)

NocII, a heptadecapeptide whose sequence lies immediately downstream of nociceptin, stimulates locomotion in mice, possibly through a novel specific receptor.

PD-117302
(CAS: 111728-01-9)

PD-117302, a new nonpeptide opioid compound, is a selective kappa-opioid agonist. It has been evaluated in vivo for antinociceptive activity and other effects c...

CAS 63631-40-3 DADLE

DADLE
(CAS: 63631-40-3)

DADLE is a prototypical δ-opioid receptor agonist with antinociceptive activity. It also exhibits activity at the μ-opioid receptor.

LY 106737
(CAS: 82970-72-7)

LY 106737 is phenylpiperidine opioid receptor antagonist, but no detailed information has been published yet.

CAS 83397-56-2 PL 017

PL 017
(CAS: 83397-56-2)

PL 017, a morphiceptin analog, is a selective μ opioid receptor agonist (IC50= 5.5 and > 10000 nM for inhibition of 125I-FK 33,824 and 125I-DADLE binding to μ a...

CAS 64963-01-5 [D-Ala2]-Leucine enkephalin

[D-Ala2]-Leucine enkephalin
(CAS: 64963-01-5)

[D-Ala2]-Leucine enkephalin is a delta opioid agonist used to study the signaling pathway of delta opioid receptors.

Chemical Structure

CAS 213130-17-7 [Phe1Ψ(CH2-NH)Gly2]Nociceptin(1-13)NH2

Quick Inquiry

Verification code

Featured Items